Abstract:Background and objective: The association between human intestinal microbes and disease is an emerging topic in microbiome research, with potential implications in cancer diagnosis. Meanwhile, immune checkpoint inhibitor (ICI) therapy has been extensively applied to cancer patients but with relatively low overall response rate owing to pathological complexity. Thus, accurate prediction of cancer onset as well as patients' response to ICI treatment through non-invasive methods, such as gut microbiome profiling, could greatly facilitate cancer diagnosis and treatment practice, which essentially improves patients' quality of life. With the rapid accumulation of microbiome sequencing data and advanced machine learning algorithms, the use of gut microbiome as predictive biomarkers presents a feasible approach to address these problems. Methods and results: The first model we built is a predictive model for classifying healthy people from patients with colon cancer (CRC). The data (originated from Curated Metagenomics Data of Human Microbiome) consists of 166 fecal samples from healthy population and equal number of CRC patients from two studies (PRJEB24748, PRJEB6070). The data were divided into training and testing sets with a 3:1 ratio. Using the training dataset, we developed a Gradient Boosting Decision Tree model. To demonstrate the model's generalizability, we evaluated it using the testing dataset and the model achieved an AUC score of 0.93 (accuracy: 89%). Moreover, using an external independent cohort (which included 52 CRC patients from PRJEB12449 and 52 healthy individuals), we obtained an AUC score of 0.94 (accuracy: 88%). We also detected bacteria highly related to CRC pathology including Solobacterium_moorei, which could be potential biomarkers for CRC diagnosis. In addition, to predict CRC patients' response to ICI, we built a random forest model based on patients' fecal microbiome data before the ICI treatment. In total, stool metagenomics data from 63 CRC patients were used, including 30 patients responding to ICI treatment and 33 non-responders. With five-fold cross-validation, we achieved training and testing AUC score of 0.89 and 0.72, respectively. With an external data with 11 CRC patients' samples, the classifier achieved an AUC of 0.78. Several microbial taxa were listed as important features contributing to the classification, e.g. Eubacterium hallii – a butyrate producer, which previously report to have a positive association with ICI clinical benefits. Conclusion: Using the non-invasive human gut microbiome data and advanced machine learning techniques, we present here two models with great performance to predict the occurrence of CRC and clinical response to ICI treatment in CRC patients. Similar strategy could be readily transferred to other cancer types to improve early diagnosis and patient stratification. Moreover, the microbial taxa identified to be essential features in the model could be developed as potential therapeutic targets. Citation Format: Die Dai, Xiaomin Xu, Wei Shen, Zhengnong Zhu, Fang Li, Xiaochen Yin, Yan Kou. Gut microbiome as a promising biomarker for colorectal cancer diagnosis and immunotherapy response prediction [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer; 2022 Oct 1-4; Portland, OR. Philadelphia (PA): AACR; Cancer Res 2022;82(23 Suppl_1) nr A030.

Efficient Mining of Anticancer Peptides from Gut Metagenome

Efficient Mining of Anticancer Peptides from Gut Metagenome (Adv. Sci. 25/2023)

Genomic Data Mining Approaches for the Discovery of Anticancer Peptides from Ganoderma Sinense.

Exploring Gut Microbiome in Predicting the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer

Effective identification and differential analysis of anticancer peptides

Derivation of a novel antimicrobial peptide from the Red Sea Brine Pools modified to enhance its anticancer activity against U2OS cells

Anticancer activities of natural antimicrobial peptides from animals

Cancer Wars: Revenge of the AMPs (Antimicrobial Peptides), a New Strategy against Colorectal Cancer

P18: Novel Anticancer Peptide from Induced Tumor-Suppressing Cells Targeting Breast Cancer and Bone Metastasis

Machine Learning-Driven Discovery and Evaluation of Antimicrobial Peptides from Crassostrea gigas Mucus Proteome

Abstract A030: Gut microbiome as a promising biomarker for colorectal cancer diagnosis and immunotherapy response prediction

Gallocin-derived Engineered Peptides Targeting EGFR and VEGFR in Colorectal Cancer: A Bioinformatic Approach

Integrating In Silico and In Vitro Approaches to Identify Natural Peptides with Selective Cytotoxicity against Cancer Cells

ACPScanner: Prediction of Anticancer Peptides by Integrated Machine Learning Methodologies

ACP-ML: A sequence-based method for anticancer peptide prediction

Computational design of anti-cancer peptides tailored to target specific tumor markers

Identification of antimicrobial peptides from the human gut microbiome using deep learning

LGBM-ACp: an ensemble model for anticancer peptide prediction and in silico screening with potential drug targets

A powerful machine learning approach to identify interactions of differentially abundant gut microbial subsets in patients with metastatic and non-metastatic pancreatic cancer

Comparative peptidome profiling reveals critical roles for peptides in the pathology of pancreatic cancer

The discovery of antimicrobial peptides from the gut microbiome of cockroach using deep learning pipeline